Nutrition for satiety and weight loss | Dr Federica Amati

What It Covers

Dr Federica Amati, head of nutrition science at ZOE and author of The Appetite Reset, explains the biology of appetite regulation across three distinct hunger types, how GLP-1 medications interact with the gut-brain satiety system, and what nutritional strategies — covering fiber, protein, and micronutrients — are required before, during, and after GLP-1 treatment to preserve muscle mass and metabolic health.

Key Questions Answered

• •Three hunger types: Hunger operates through three distinct mechanisms: homeostatic (biological energy deficit), hedonic (brain-driven desire for specific flavors or textures), and microbiota-driven (gut microbes signaling for their preferred substrates via vagal nerve pathways). A practical way to distinguish hedonic from homeostatic hunger is specificity — hedonic hunger targets a particular food, while homeostatic hunger accepts almost anything available. Recognizing which type is active helps determine whether eating is biologically necessary or environmentally triggered.
• •Four-phase satiety signaling: A well-composed meal activates satiety across four sequential phases: sensory (sight, smell, taste priming the brain), gastric (stomach stretch receptors activated by high food volume), small intestinal (protein, complex carbohydrates, and healthy fats triggering GLP-1 release from L cells), and colonic (fiber and healthy fats sustaining PYY and GLP-1 release two to three hours post-meal). Eating distracted or consuming liquid meals bypasses multiple phases, significantly reducing satiety duration.
• •GLP-1 medication non-response rates: Up to 20% of real-world GLP-1 users lose no weight even at maximum dose, compared to 5–10% non-response in closely monitored clinical trials. The gap exists because trials include mandatory dietitian support, structured resistance exercise three times weekly, and psychological counseling — none of which are standard in typical prescriptions. Without this infrastructure, up to 40% of weight lost can come from lean muscle mass rather than fat tissue.
• •Muscle preservation requires resistance training over protein alone: Resistance training three times per week is more critical than protein intake for preserving lean mass during GLP-1 treatment. Protein targets of 1.2–1.6 grams per kilogram of body weight are recommended, but protein intake without resistance training cannot prevent muscle loss. On dose-increase days when appetite is most suppressed, adding pea or soy protein isolate to a smoothie is a practical strategy to meet protein targets without requiring high food volume.
• •Gut prehabilitation reduces GLP-1 side effects: Spending several weeks before starting GLP-1 medication improving gut microbiome health significantly reduces the likelihood of nausea, constipation, and reflux — the most common reasons for discontinuation. The protocol involves gradually increasing fiber diversity toward 30 different plant foods per week (including nuts, seeds, herbs, spices, pulses, fruits, and vegetables), adding omega-3 fatty acids, and resolving pre-existing constipation. Entering treatment with existing gut dysfunction worsens GI side effects and reduces drug efficacy.
• •Fiber targets remain at 30g daily during GLP-1 treatment: Despite significantly reduced calorie intake on GLP-1 medications, the fiber target does not decrease. Most US adults consume only 12–14 grams daily against a recommended 30 grams. During treatment, fiber supplementation becomes a practical tool because it delivers gut microbiome substrate without adding problematic food volume. Maintaining fiber intake also potentiates endogenous satiety hormone production, which can lower the effective dose needed and reduce side effects simultaneously.
• •Leptin resistance explains hunger in obesity: In people living with chronic obesity, fat cells continuously release leptin to signal adequate energy stores, but the brain becomes resistant to the signal — analogous to insulin resistance in type 2 diabetes. The result is genuine, biologically driven hunger despite excess stored energy. GLP-1 medications override this resistance by amplifying satiety signaling directly. This mechanism also explains why willpower-based comparisons between individuals are physiologically inaccurate, since hypothalamic wiring differs based on genetics and in-utero epigenetic factors.